Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021
Open Access
- 8 April 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (20) , 2015-2018
Abstract
In June 2020, preliminary results for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial conducted in the UK indicated benefit from dexamethasone in severely ill hospitalized patients with COVID-19 but potential harm in those not requiring oxygen.1,2 In October 2020, the National Institutes of Health (NIH) issued COVID-19 treatment guidelines advising against systemic corticosteroid use in patients with mild to moderate COVID-19.1 Using 2 large US health care claims databases, we examined systemic corticosteroid use among nonhospitalized patients with COVID-19.Keywords
This publication has 4 references indexed in Scilit:
- Faculty Opinions recommendation of Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support.2021
- Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory supportEuropean Respiratory Journal, 2021
- A COVID‐19‐ready public health surveillance system: The Food and Drug Administration's Sentinel SystemPharmacoepidemiology and Drug Safety, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021